Evidence map›Paper›PMID 41090865›Full record

ArticleNanomaterials (Basel, Switzerland)2025

Radiosensitization by Docetaxel Prodrug-Loaded Lipid Nanoparticles in Pancreatic Cancer Xenografts.

Abdulaziz Alhussan, Nolan Jackson, Nancy Dos Santos, Sam Chen, Yuen Yi C Tam, Devika B Chithrani

Abstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Abdulaziz AlhussanDepartment of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.ORCID 0000-0002-9920-2803
Nolan JacksonDepartment of Physics and Astronomy, University of Victoria, Victoria, BC V8P 5C2, Canada.
Nancy Dos SantosDepartment of Experimental Therapeutics, British Columbia Cancer-Vancouver, Vancouver, BC V5Z IL3, Canada.
Sam ChenIntegrated Nanotherapeutics Inc., Burnaby, BC V5G 4X4, Canada.ORCID 0000-0002-3738-6600
Yuen Yi C TamIntegrated Nanotherapeutics Inc., Burnaby, BC V5G 4X4, Canada.
Devika B ChithraniDepartment of Physics and Astronomy, University of Victoria, Victoria, BC V8P 5C2, Canada.ORCID 0000-0001-5251-1388

Funding

Canada Foundation for Innovation (CFI) John R. Evans Leaders Fund (JELF)Government of British Columbia British Columbia Knowledge Development Fund (BCKDF)Kuwait Foundation for the Advancement of Sciences (KFAS) CB21-63SP-01NanoMedicines Innovation Network (NMIN) Strategic Initiative fundthe Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grantthe University of Victoria Collaborative Health Grant
6 · The paper itself

Abstract

Cancer treatments are limited by poor tumor specificity and toxicity. We tested a radiosensitizing approach using PEG/RGD-functionalized gold nanoparticles (GNPs), a lipid-nanoparticle-encapsulated docetaxel prodrug (LNP

Indexed as

cancercombined modality therapydocetaxeldocetaxel prodruggold nanoparticleslipid nanoparticlesnanotechnologyradiosensitizationradiotherapy

Identifiers

PMID41090865
PMCPMC12526313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.